Myriad Genetics Earnings Preview: Get Ahead of the Analysts
Myriad Genetics (NASDAQ:MYGN) will report earnings after markets close on Tuesday, August 13th. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
Here is your Cheat Sheet to Myriad Genetics Earnings:
Earnings Expectations: Analysts expect earnings of $0.44 per share on revenues of $159.87 million. Currently, the company’s P/E ratio stands at 18.90.
Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a profit of $0.42 to a profit $0.43. For the current year, the average estimate is a profit of $1.67, which is better than the estimate ninety days ago.
Here’s how Myriad Genetics has been performing on an annual basis:
|Revenue ($) in millions||327||363||402||496|
|Diluted EPS ($)||0.86||1.54||1.10||1.30|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||132.96||133.44||149.14||156.47|
|Diluted EPS ($)||0.34||0.36||0.42||0.46|
Myriad Genetics has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!